Financial Performance Overview

BioNTech SE has announced a significant financial update for the fourth quarter of fiscal 2024, revealing a total revenue of €1.2 billion. This figure represents a 24.4% decrease compared to the same period in the previous year but still managed to exceed analysts' expectations. The company also reported a net profit of €259.5 million, a decrease from €457.9 million in 2023, with diluted earnings per share (EPS) at €1.08, down from €1.88 a year ago.

Annual Financial Highlights

For the entire fiscal year 2024, BioNTech's total revenues amounted to €2.7 billion, a decline from €3.8 billion in 2023. The diluted loss per share was reported at €2.77, contrasting sharply with the €3.83 earnings per share in the previous year.

Strategic Advancements and Market Reaction

CEO Ugur Sahin highlighted the company's significant progress in its oncology pipeline, including the initiation of global Phase 3 clinical trials for the anti-PD-L1/VEGF-A bispecific antibody candidate BNT327 and key data updates from mRNA cancer immunotherapy programs. Following the earnings report, BioNTech's shares in the United States experienced a 1.93% drop in premarket trading.